CategoryLab Lessons

I must have Wind as it seems I keep repeating myself

Todays B cell burp was reported as it came out of the Horse’s mouth when it came out at ECTRIMS2019, so I am not going to dwell on the take home message that it was positive and inhibited relapsing MS. This was an interesting trial design that recruitment was continued until set points were reached to ensure the trial delivered an answer. “Ofatumumab was associated with lower...

Ocvrelizumab can blunt the anti-COVID19 antibody response.

We have recently reported on the the possibility that taking ocrelizumab may reduce your chance of producing protective antibody against COVID-19-related virus. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S.Clin Exp Immunol. 2020 Jul 16. doi: 10.1111/cei.13495. Online...

Neurofilament and vitamin D supplementation

In a moderately sized study from Finland, investigators wanted to know whether the addition of vitamin D to interferon-beta-1b (a first line disease modifying treatment) had a favourable outcome on disease activity. In order to assess this they measured serum (blood) neurofilament levels a protein found in neurones as a marker of MS disease activity. What they found was that the addition of...

Ozanimod How does it work? Have we got a real clue?

Last week I wrote a post about how pharma may report on the next Cladrimod (cladribine or ozanimod/posenimod) study in “Dr Dooley will be happy that their uncited work from 2016 has been repeated….MS drugs affect memory B cells!”. In that post I made a prediction on how the lymphocyte subset data would be reported from the next MS drug so that the potential for memory B cell depletion...

Ocrelizumab inhibts vaccine responses

Ocrelizumab blunts the vaccination response this is shown in a trial if you want to read about it straight from the Horses mouth you can read below but it is behind a pay wall, if you want to see what was shown you can see it for free here. Baker D, Roberts CA, Pryce G, et al. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases [published online ahead of print, 2020...

How to control temperature-sensitivity of nerve function

You may know that symptoms can get worse when you are too hot and this is because temperature can affect how nerves function. We have been looking into the reasons behind this and can see a way to potentientially reduce this Mark Baker Mechanism of sodium ion movement in optic nerve axons and implications for MS Energy deficit in neurons and axons is part of the zeitgeist of present-day MS...

Specificity of oligoclonal bands…Viruses?

Recombinant antibodies derived from laser captured single plasma cells of multiple sclerosis brain identified phage peptides which may be used as tools for characterizing intrathecal IgG response.Kennedy PGE, Graner MW, Walker D, Pointon T, Fringuello A, Yu X.J Neuroimmunol.2020 Jul 14;347:577319. doi: 10.1016/j.jneuroim.2020.577319. Online ahead of print. Oligoclonal bands and...

Dr Dooley will be happy that their uncited work from 2016 has been repeated….MS drugs affect memory B cells!

Part of the scientific process is repetition, but at some point in time you need to believe it and move one. This study is Open access and so you can read it, but it is further supportive evidence of the memory B cell hypothesis Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K. EBioMedicine. 2017;...

Remyelination. Is this war amongst scientists?

Remyelination is a hot topic In the paper below they say “The view that differentiation of OPC into mature myelinating oligodendrocytes is required for successful remyelination in humans has been challenged recently. Measuring the integration of 14C derived from nuclear testing into DNA of oligodendroglial lineage cells Yeung et al. suggest that pre-existing oligodendrocytes and not...

How to reduce the time to Siponimod

How to reduce the delay of diagnosing secondary progression in multiple sclerosis. Hernan Inojosa, Tjalf Ziemssen July 22, 2020 Letterhttps://doi.org/10.1177/1352458520943799 Do you have secondary progressive MS?. This article points you to a tool devleoped by Novartis who are the makers of Siponimod . This has been licenced for secondary progressive MS so you need to know when this begins It is...

Translate

Categories

Recent Posts

Recent Comments

Archives